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Cerebral oedema is a major cause of neurological disability and
morbidity in human malignant glioma patients. Steroid medica-
tions are the most effective pharmacological agents for the control
of cerebral oedema in human brain tumour patients. However,
prolonged steroid therapy has significant side-effects, including
mental changes, immunosuppression, Cushing syndrome and
osteoporosis. Moreover, steroids stabilize blood–brain and
blood–tumoural barriers, reduce tumour perfusion and inhibit
apoptosis in human malignant glioma cells (Weller et al, 1997a;
Naumann et al, 1998). These changes may interfere with the
efficacy of adjuvant chemotherapy for malignant gliomas.
Alternative agents for the treatment of cerebral oedema in
glioma patients are therefore urgently needed. Boswellic acids are
phytotherapeutic agents obtained from the gum resin of Boswellia
serrata which have been attributed anti-inflammatory properties
and therapeutic effects, e.g. in inflammatory bowel disease and
rheumatoid arthritis (Ammon, 1996; Gupta et al, 1997). These
actions may be mediated by the inhibition of 5-lipoxygenase (5-
LOX) (Safayhi et al, 1992, 1995; Sailer et al, 1996) and leucocyte
elastase (Safayhi et al, 1997). Preliminary clinical data suggest
that the drug formulation ‘H15’, which contains boswellic acids as
putative active ingredients, has beneficial effects on the cerebral
oedema in human glioma patients (Böker and Winking, 1997).
Moreover, the same authors have reported that orally adminis-
tered, tolerable doses of H15 (240 mg kg–1) inhibit the growth of
intracranially growing C6 gliomas in the rat (Winking et al, 1998).
Here, we characterize the effects of boswellic acids on human
glioma cells in-vitro and examine whether these agents interfere
with apoptotic cell death of glioma cells after exposure to
chemotherapeutic drugs and the CD95 ligand (CD95L).
MATERIALS AND METHODS
Chemicals
Amyrin, a mixture of isomeric a- and b-forms, was purchased from
Roth (Karlsruhe, Germany). The boswellic acids, acetyl-11-keto-b-
boswellic acid (AKBA), b-boswellic acid and acetyl-b-boswellic
acid were isolated from the resin of Boswellia serrata and purified as
described (Safayhi et al, 1992, 1995). All boswellic acids were
dissolved in dimethylsulphoxide at 20 mM, except amyrin (4 mM).
Aliquots were stored at –20°C. Cycloheximide (CHX), actinomycin
D (ActD), doxorubicin, vincristine, cytarabine, N-tert-butyl-a-
phenylnitrone (PBN), superoxide dismutase (SOD) and N-acetyl-
cysteine (NAC) were purchased from Sigma (St Louis, MO, USA).
Topotecan was obtained from SmithKline Beecham (King of Prussia,
PA, USA), CCNU from Medac (Hamburg, Germany) and teniposide
(VM-26) from Bristol (Munich, Germany). Radiochemicals were
from Amersham (Braunschweig, Germany) and protease inhibitors
from Bachem (Heidelberg, Germany). Terminal transferase, biotin-
dUTP, streptavidin alkaline phosphatase conjugate, nitroblue tetra-
zolium chloride (NBT) and 5-bromo-4-chloro-3 indolyl phosphate
(BCIP) for in situ DNA end labelling were obtained from Boehringer
(Mannheim, Germany). 2¢,7¢-Dichlorodihydrofluorescein diacetate
(DCF-H2) was purchased from Molecular Probes (Groningen, The
Netherlands). Soluble CD95L was obtained from CD95 ligand
cDNA-transfected N2A neuroblastoma cells (Roth et al, 1997).
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Cell lines and cell culture
LN-18, LN-229 and LN-308 cells were kindly provided by Dr N
de Tribolet (Lausanne, Switzerland). T98G were obtained from
ATCC (Rockville, MD, USA). LN-229 cells are heterozygous for
p53 and develop p53 transcriptional activity whereas LN-18 and
T98G cells are mutant for p53. LN-308 cells do not express any
p53 protein (Van Meir et al, 1994; Weller et al, 1998). The human
glioma cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS),
1m M glutamine and 1% penicillin–streptomycin. HCT116 cells
were cultured in McCoy’s 5A medium supplemented with 10%
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Figure 1 Boswellic acid toxicity of human glioma cells: requirement for new protein synthesis but no role for reactive oxygen species. (A–D) T98G, LN-229,
LN-18 or LN-308 human malignant glioma cells were seeded in 96-well plates (104 per well) for 24 h and then exposed to amyrin (n), AKBA (l l), b-boswellic
acid (s) or acetyl-b-boswellic acid (s s) for 48 h. Survival and proliferation were assessed by crystal violet assay. Data are expressed as mean percentages and
s.e.m. (n = 3). (E) LN-229 (black bars) or T98G (open bars) cells were exposed to AKBA (20 mM) for 16 h in the absence or presence of ActD (0.5 mg ml–1) or
CHX (10 mg ml–1). At these concentrations, RNA synthesis at 7–8 h was inhibited by ActD by 90% and 88%, and protein synthesis by CHX by 79% and 92% in
LN-229 and T98G respectively (data not shown). Data are expressed as mean percentages of survival and s.e.m. relative to untreated cells or cells exposed to
the macromolecular inhibitors alone (*P < 0.05, t-test). (F) LN-229 (black bars) or T98G (open bars) cells were treated with AKBA (20 mM) without or with a 2 h
preexposure and a 48 h co-exposure to NAC (1 mM), SOD (50 U ml–1) or PBN (100 mM). Data are expressed as in (E)758 T Glaser et al
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FCS and 1% penicillin–streptomycin. Rat neonatal astrocytes were
prepared as previously described (Weller et al, 1997b).
Cytotoxicity assays were performed in medium containing 5%
FCS. The generation of glioma cell clones expressing murine BCL-
2 or murine p53 val135 proteins has been described (Weller et al,
1995a; Wagenknecht et al, 1997b; Trepel et al, 1998). Glioma cells
expressing CRM-A were obtained by electroporation (Biorad Gene
Pulser, 250 V, 950 mF) using the pEFR CRM-A flag puro plasmid
(Strasser et al, 1995). Transgene expression was assessed by
immunoblot analysis for murine BCL-2 and p53 protein (Weller et
al, 1995a; Trepel et al, 1998) and by Northern blot analysis for
CRM-A mRNA (Wagenknecht et al, 1998). Experiments were
performed with control transfectants harbouring plasmids without
insert (neo for BCL-2, hygro for p53, puro for CRM-A).
Viability and apoptosis studies
The procedures for crystal violet staining, in-situ DNA end labelling,
quantitative DNA fluorometry and electron microscopy have been
published in detail (Weller et al, 1994, 1997b). The MTT assay
(3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide) was
used to determine viability in HCT116 colon carcinoma cells.
Biochemical studies
For the determination of RNA synthesis, the cells were grown in 12-
well plates (104 cells ml–1) and treated as indicated for 8 h. The cells
were pulse labelled with 0.5 mCi ml–1 [5,6-3H]uridine (specific
activity: 40 Ci mmol–1) from 7–8 h, washed with ice-cold phosphate-
buffered saline (PBS) (23) and ice-cold 6% trichloroacetic acid (23)
to remove unincorporated, acid-soluble label, and lysed with 0.1 N
NaOH (1 ml) overnight at room temperature. Then, 0.5 ml of the
lysate was mixed with 4 ml scintillation cocktail and counted in a
liquid scintillation counter. For the determination of protein
synthesis, the cells were pulse labelled during the last hour of incuba-
tion with 1 mCi ml–1 L-[4,5-3H]leucine (specific activity: 167 Ci
mmol–1). After washing with ice-cold PBS (33), the cells were lysed
with 0.1% sodium dodecyl sulphate (SDS) (0.5 ml per well) for
30 min at 37°C. Proteins were precipitated by addition of ice-cold
15% trichloroacetic acid (0.5 ml per well) and pelleted by centrifuga-
tion (13 000 rpm, 10 min, 4°C). The supernatant (trichloroacetic
acid-soluble fraction) was counted in a liquid scintillation counter
after addition of 5-ml scintillation cocktail. The pellet (trichloroacetic
acid-precipitable fraction) was washed with 6% trichloroacetic acid
(33), dissolved in 0.5 ml 0.1 N NaOH, and the radioactivity of the
precipitated proteins measured after addition of 5-ml scintillation
cocktail.
Cleavable DNA topoisomerase complex formation induced by
classical inhibitors of topoisomerase I or II was assessed by potas-
sium chloride precipitation as described (Rowe et al, 1986; Winter
et al, 1998).
The generation of reactive oxygen species was monitored using
the fluorescent probe, DCF-H2 (Reber et al, 1998). Immunoblot
analysis was performed as described (Weller et al, 1994). The
primary antibodies were anti-p53 Ab-2 (Oncogene Science,
Uniondale, NY, USA; 2.5 mgm l –1), anti-BCL-2 (Dakopatts,
Glostrup, Denmark; 2 mg ml–1) and anti-BAX (Santa Cruz, CA,
USA; 2 mg ml–1). Flow cytometric analysis of CD95 expression was
performed as described (Weller et al, 1995b) using fluorescein
isothiocyanate (FITC)-UB2 anti-Fas antibody from Immunotech
(Hamburg, Germany) and FITC-mouse IgG1 from Sigma (St Louis,
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Figure 2 Induction of apoptosis in human LN-229 malignant glioma cells by
AKBA, but not amyrin. LN-229 cells were either untreated (A) (´ 250) or
exposed to 20 mM amyrin (B) (´ 250) or 20 mM AKBA (C) (´ 400) for 48 h and
processed for in-situ DNA end labelling as described (Weller et al, 1994,
1997b) to detect the presence of DNA breaks characteristic of apoptosis.
Note the high number of labelled nuclei after exposure to AKBA. No specific
labelling was obtained when the co-factor for terminal transferase, cobalt
chloride, was omittedBoswellic acids for malignant glioma 759
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MO, USA) as isotype control antibody. Immunolabelling was quan-
tified as specific fluorescence index (SFI) defined by the ratio of the
mean cellular fluorescence with specific versus control antibody.
Cell cycle analysis
For cell cycle analysis, the glioma cells were treated as indicated,
washed with PBS, incubated with trypsin for 3 min at 37°C,
harvested, washed and fixed with 70% ice-cold ethanol. A total of
106 cells per condition were stained with propidium iodide
(50 mg ml–1) in PBS containing 100 U ml–1 RNase A) for 30 min.
All samples were analysed on an FacsCalibur flow cytometer
using the Cell Quest acquisition and analysis software (Becton
Dickinson, Heidelberg, Germany).
RESULTS
Boswellic acids induce apoptosis in human malignant
glioma cells
To determine cytotoxic and antiproliferative effects of the boswellic
acids, the glioma cells were exposed to different boswellic acids for
0–48 h. Figure 1A–D shows that all four glioma cell lines were
susceptible to boswellic acid-induced growth inhibition in a concen-
tration-dependent manner and that the order of potency of the
compounds evaluated was similar in all cell lines. Acetyl-b-
boswellic acid was most potent, followed by AKBA and b-
boswellic acid, whereas amyrin had only minor effects. When the
cells were seeded at low density, exposed to the drugs for 24 h, and
then allowed to recover for 5–10 generation times, there was no
significant decrease in the EC50 values (data not shown), suggesting
that the acute cytotoxic effects shown in Figure 1A–D are respon-
sible for the inhibition of clonogenic survival in the pulse/recovery
colony formation assays. Next, we asked whether the susceptibility
to boswellic acids was specific for the neoplastic phenotype of
glioma cells or could also be observed in untransformed rat neonatal
astrocytes. To this end, we exposed the astrocytes to the boswellic
acids as done with the glioma cells in Figure 1. We found that the
proliferating neonatal rat astrocytes were no more resistant to
boswellic acid cytotoxicity than the malignant glioma cell lines, that
is, approximate EC50 values for cytotoxicity are 20 mM for AKBA,
27 mM for acetyl-b-boswellic acid and 40 mM for b-boswellic acid.
Light microscopic monitoring suggested that boswellic acid-
induced growth inhibition of glioma cells was associated with the
induction of apoptosis. This was confirmed by in situ DNA end
labelling (Figure 2) and electron microscopy (Figure 3). In-situ
DNA end labelling revealed a high number of cells harbouring
DNA breaks after exposure to AKBA, whereas there was no
difference in labelling between untreated cells and amyrin-treated
cells (Figure 2), corresponding to the toxicity data (Figure 1 A–D).
Similarly, AKBA, but not amyrin, induced classical features of
apoptotic cell death as assessed by electron microscopy (Figure 3).
Exposure to AKBA, but not amyrin, induced a moderate degree of
DNA fragmentation up to 10% of the total DNA, a value that is
consistent with the minor degree of DNA fragmentation induced
by other pro-apoptotic stimuli in these cells, including CD95L
(data not shown).
AKBA-induced glioma cell apoptosis requires new
protein synthesis but does not involve reactive oxygen
species formation
AKBA-induced cell death was attenuated by a protein synthesis
inhibitor, CHX, but unaffected by the RNA synthesis inhibitor,
ActD (Figure 1E), suggesting that translation of preexisting
mRNA mediates AKBA toxicity. AKBA did not induce the forma-
tion of reactive oxygen species (data not shown), and the anti-
oxidants NAC, SOD and PBN did not block AKBA toxicity
(Figure 1F). Ethacrynic acid was used as a positive control for
reactive oxygen species formation (Reber et al, 1998), and
A
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Figure 3 AKBA-induced apoptosis of LN-229 cells: transmission electron
microscopy. LN-229 cells were exposed to AKBA (20 mM) for 24 h or 48 h and
processed for electron microscopy as described (Weller et al, 1994). (A)
(´ 2500) shows the appearance of untreated cells, (B) and (C) show different
stages of apoptosis 24 h and 48 h after treatment with AKBA. In (B) (´ 5700),
there is a typical early apoptosis with cytoplasmic blebbing and condensed
nuclear heterochromatin. In (C) (´ 2200), both apoptotic (arrows) and
necrotic cells are visible760 T Glaser et al
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Figure 4 Boswellic acid toxicity: the role of apoptosis control gene products. (A) LN-229 cells (upper panel) and LN-18 (lower panel) were either untreated
(control) or exposed to AKBA or amyrin at 20 mM. After 2, 4 or 8 h p53, BAX, BCL-2 and p21 protein expression were examined by immunoblot analysis as
described (Weller et al, 1997c). (B) Parental HCT116 human colon carcinoma cells (p21 +/+, n) or sublines with heterozygous (+/–, •) or homozygous (–/–, s s)
p21 gene deletions were seeded in 96-well plates (104 per well) for 24 h and then exposed to AKBA for 48 h. Survival was assayed by the MTT assay. Data are
mean percentages and s.e.m. (n = 3). (C, D) LN-229 and LN-18 hygro or p53-transfected cells were maintained at 38.5°C and treated with AKBA (10 mM, black
bars; 20 mM, open bars) for 48 h (C) or shifted to 32.5°C for 4 h prior to AKBA exposure for 48 h (D) (30 mM, black bars; 40 mM, open bars) (*P < 0.05, t-test).
(E, F) LN-229 and LN-18 neo or BCL-2-transfected cells (E), or LN-229 and LN-18 puro or CRM-A-transfected cells (F) were exposed to AKBA at 10 mM (black
bars) or 20 mM (open bars). Data in B–F are expressed as mean percentages of survival and s.e.m. (n = 3)Boswellic acids for malignant glioma 761
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potassium-deprived cerebellar granule neurons served as a biolog-
ical control for the prevention of apoptosis by the antioxidants
(Schulz et al, 1996).
Boswellic acid toxicity: the role of p53, p21, BCL-2,
BAX and caspases
To examine the role of major apoptosis control genes in boswellic
acid-induced apoptosis, we exposed the glioma cells to AKBA and
monitored the expression of p53, p21, BCL-2 and BAX proteins.
Figure 4A shows that AKBA neither induces p53 protein accumu-
lation in LN-229, which are wild-type for p53, nor in LN-18,
which express mutant p53 protein. AKBA also failed to alter the
levels of BAX or BCL-2 proteins, except for a minor reduction of
BCL-2 protein at 8 h after AKBA exposure in LN-18 cells.
Interestingly, there was a time-dependent accumulation of p21 in
both cell lines after exposure to AKBA (20 mM), including p53-
mutant LN-18 cells, indicating that p21 expression is induced in a
p53-independent manner.
p21 inhibits cyclin-dependent kinase (cdk) activity and medi-
ates the p53-controlled cell cycle arrest in G0/1. However, cell
cycle analysis after exposure to AKBA revealed no specific
pattern of cell cycle redistribution in LN-229 or LN-18 cells
despite the induction of p21 expression (data not shown). This
may be a consequence of the RB checkpoint disruption in both cell
lines which we have been able to link to a homozygous deletion of
p16 in both cell lines (Wagenknecht et al, 1997b; Weller et al,
1998).
To further examine the role of p21 in AKBA toxicity, we
compared the effects of AKBA toxicity in HCT116 colon carci-
noma cells which were either wild-type or had a heterozygous or
homozygous deletion of the p21 gene (Waldman et al, 1995,
1996). The wild-type cells expressed high levels of p21 constitu-
tively that were not enhanced further by AKBA (data not shown).
The wild-type cells were more resistant to AKBA than the
sublines with heterozygous or homozygous p21 deletions (Figure
4B), suggesting that p21 is not a down-stream effector of AKBA
toxicity but confers relative protection from apoptosis, as has been
hypothesized for p53-mediated p21 induction (Gomez-Manzano et
al, 1997; Trepel et al, 1998).
To examine the role of p53 in AKBA toxicity in more detail, we
took advantage of LN-18 and LN-229 transfectants expressing the
temperature-sensitive p53 val135 mutant that behaves as a mutant
p53 protein at 38.5°C but adopts wild-type conformation and
activity at 32.5°C (Michalowitz et al, 1990; Trepel et al, 1998). At
38.5°C (mutant p53), the p53-transfected cells were as sensitive to
AKBA as hygro control cells (Figure 4C). The shift from 38.5°C
to 32.5°C per se reduced drug sensitivity, presumably due to
significantly slower proliferation of hygro control cells, reduced
metabolic activity and growth arrest of p53 clones at this tempera-
ture (Wagenknecht et al, 1997b). Compared with isogenic hygro
controls, wild-type p53-expressing cells (32.5°C) were more
sensitive to AKBA-induced apoptosis (Figure 4D), even though
p21 is induced by p53 under these conditions (Trepel et al, 1998).
Next, we examined whether ectopic expression of BCL-2 or of
the viral caspase inhibitor, CRM-A, affected AKBA toxicity.
Figure 4E and F show that neither BCL-2 nor CRMA-A protected
LN-18 or LN-229 cells from AKBA-induced apoptosis. To
confirm that caspases were not involved in AKBA toxicity of
glioma cells, we showed that the caspase 1 (ICE)-type peptide
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Figure 5 AKBA does not modulate cancer drug toxicity of human malignant glioma cells. LN-229 cells were either untreated or pretreated with 2.5 mM AKBA
for 24 h and then exposed to topotecan (A), VM-26 (B) or CCNU (C) in the absence (filled symbols) or presence (open symbols) of AKBA (2.5 mM). (D) LN-229
cells were untreated or pretreated to increasing concentrations of AKBA for 24 h and then co-exposed to the drugs for 72 h (n, AKBA only; n n, 0.25 mM
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mean percentages of survival and s.e.m. (n = 3)762 T Glaser et al
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Figure 6 AKBA enhances CD95L-induced apoptosis of human glioma
cells. (A, B) T98G (A) or LN-229 (B) were exposed to CD95L alone (l l) or
CD95L plus amyrin (20 mM) (s s) or CD95L plus AKBA (20 mM) (n) for 48 h.
Data are expressed as mean percentages of survival and s.e.m. (C, D) LN-
229 cells were untreated (C) or exposed to AKBA (20 mM) (D) for 24 h. CD95
expression was assessed by flow cytometry. The SFI values (control: 1.35;
AKBA: 1.15), were not significantly different. (E, F) T98G, LN-18 or LN-308
cells were exposed to amyrin (20 mM) (black bars), AKBA (20 mM) (grey bars)
and in (E) ActD (1 mg/ml–1), or in (F) CHX (10 mg ml–1) (open bars) for 8 h.
RNA (E) and protein (F) synthesis were determined during the last hour
(7–8) of incubation as described in Methods. Data are mean percentages
and s.e.m. (*P < 0.05, t-test). (G) T98G cells were untreated or exposed to
AKBA (20 mM), amyrin (20 mM), topotecan (20 mM) or VM26 (10 mM) for
30 min. Cleavable DNA topoisomerase complexes were measured as
described in MethodsBoswellic acids for malignant glioma 763
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inhibitor, Ac-YVAD-chloromethylketone (YVAD-CMK), and the
caspase 3 (CPP32)-type peptide inhibitor, aspartic acid aldehyde
(DEVD-CHO), failed to inhibit AKBA toxicity (data not shown).
In contrast, ectopic expression of BCL-2 or CRM-A or exposure to
the peptide inhibitors attenuated CD95 ligand-induced apoptosis
of these cells (Weller et al, 1995a) (data not shown).
Boswellic acids do not modulate chemotherapeutic
drug-induced cytotoxicity but synergistically enhance
CD95L-induced apoptosis via inhibition of RNA
synthesis
In contrast to dexamethasone, which inhibits chemotherapeutic
drug-induced apoptosis of glioma cells (Weller et al, 1997a),
subtoxic concentrations of AKBA did not interfere with the cyto-
toxic and anticlonogenic actions of several chemotherapeutic
drugs, including cytarabine, CCNU, doxorubicin, topotecan,
vincristine and VM26. There was also no augmentation of drug
toxicity by AKBA. These experiments were done with T98G and
LN-229 cells and were performed as in Figure 1A for acute cyto-
toxicity, and using a 24 h pulse at very low seeding density with
5–10 generation times recovery for assessing effects on clono-
genicity. We evaluated combinations of three concentrations of
AKBA and four concentrations of each cancer chemotherapy
drug. A representative example of these overall negative data is
illustrated in Figure 5.
Conversely, CD95L-induced apoptosis was synergistically
enhanced by AKBA (Figure 6 A,B). This effect was not related to
AKBA-induced increases in CD95 expression (Figure 6 C,D).
Potentiation of apoptosis by inhibitors of RNA and protein
synthesis such as ActD or CHX is paradigmatic for the cell death
induced by cytokines such as CD95L and tumour necrosis factor
(TNF)-a (Weller et al, 1994). Similarly, the concentrations of
AKBA required for synergistic glioma cell killing (Figure 6A)
induced prominent inhibition of RNA synthesis (Figure 6E),
suggesting that an ActD-like effect mediates synergy of AKBA
with CD95L. Protein synthesis was not affected (Figure 6F).ActD
and CHX served as positive controls for the inhibition of RNA and
protein synthesis. Parallel experiments assessing the concentra-
tion–response relation for the effects of AKBA on (i) CD95L-
induced glioma cell killing and (ii) inhibition of RNA synthesis
revealed that both effects were intimately linked (data not shown).
In contrast to classical inhibitors of topoisomerase I or II, e.g.
camptothecin or VM26, which were used as positive controls,
AKBA did not induce the formation of cleavable DNA topoiso-
merase complexes (Figure 6G).
DISCUSSION
Boswellic acids are putative 5-LOX inhibitors which may have a
role in the management of various inflammatory conditions and in
the control of cerebral oedema in brain tumour patients. These
agents seem to block 5-LOX activity by direct interaction with the
enzyme at a binding site different from the catalytic centre. Recent
data support that the planar pentacyclic ring system is crucial for
enzyme binding, but only compounds containing a hydrophilic
group on C-4 and a keto-function on
C-11, e.g. AKBA, are able to inhibit 5-LOX activity completely.
Modulation or elimination of these two functional groups attenu-
ates (e.g., b-boswellic acid and acetyl-b-boswellic acid) or abro-
gates (e.g. amyrin) the inhibitory effect on 5-LOX activity. Here,
we show that boswellic acids induce apoptosis in human malig-
nant glioma cells (Figures 1–3, Table 1). While acetyl-b-boswellic
acid is the most toxic substance among the tested boswellic acids,
AKBA is the most potent 5-LOX inhibitor, with an IC50 of 1.5 mM
in Ca2+/ionophore-stimulated intact polymorphonuclear neutro-
phils (Safayhi et al, 1992) and presumably in glioma cells (Heldt et
al, 1997). Importantly, amyrin, which is devoid of toxic effects, is
also not a LOX inhibitor, suggesting that the functional groups
responsible for inhibition of 5-LOX activity also mediate the
effects on viability of the glioma cells. Yet, the IC50 values for
LOX inhibition are 10 to 20-fold lower than those required for
cytotoxicity (Figure 1 A–D) (Heldt et al, 1997).
We find that AKBA-induced apoptosis requires new protein, but
not RNA synthesis, and does not involve the generation of reactive
oxygen species (Figure 1 E,F). The levels of BAX and BCL-2 are
unaltered, and ectopic expression of BCL-2 does not inhibit apop-
tosis (Figure 4 A,E). The failure of ectopic CRM-A expression or
pseudosubstrate enzyme inhibitors to abrogate apoptosis indicates
that caspase activation may not be required for AKBA-induced
apoptosis (Figure 4F). These data make sense in that caspase-
dependent apoptotic cell deaths are predicted to be inhibited
by BCL-2, as e.g. CD95-mediated apoptosis in glioma cells
(Wagenknecht et al, 1998).
Exposure to cytotoxic concentrations of AKBA does not acti-
vate p53 activity in a wild-type p53-containing cell line, LN-229
(Figure 4A). However, ectopic expression of a temperature-sensi-
tive p53 val135 mutant facilitates AKBA-induced apoptosis when
the grafted protein is expressed at wild-type conformation (Figure
4D). p21, the major p53 response protein associated with growth
arrest in G0/1, was induced by AKBA in cells with wild-type (LN-
229) or mutant (LN-18) p53 status (Figure 4A), suggesting that
AKBA activates a p53-independent pathway of p21 expression.
Table 1 Summary of data on boswellic acid cytotoxicity of human malignant glioma cells
Role in boswellic acid-induced apoptosis of human glioma cells
CD95 No changes in CD95 expression at the cell surface
CD95L Synergy with boswellic acids in inducing apoptosis
Bax Expression levels remain unaltered
Bcl-2 Expression levels remain unaltered
p53 No activation, but wild-type p53 gene transfer facilitates boswellic acid-induced apoptosis
p21 Induced, appears to be implicated in protection from boswellic acid-induced apoptosis
Caspases No role for CRM-A-, YVAD-or DEVD-sensitive caspases764 T Glaser et al
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Interestingly, AKBA-induced p21 expression did not result in a
growth arrest in G0/1 or G2/M. However, when glioma cells are
growth-arrested by p53 val135 in wild-type conformation, p21 is
also induced (Wagenknecht et al, 1997b) but the cells stably arrest
in G2/M (Weller, unpublished observation), suggesting that p21
expression per se does not determine the type of cell cycle arrest in
glioma cells. That p53-dependent p21 expression failed to induce
G0/1 arrest in LN-18 and LN-229 cells, was consistent with the
disruption of the RB checkpoint in these cells, a target of p21-
mediated G0/1 arrest, via loss of both p16 alleles (Weller et al,
1998).
The facilitation of AKBA-induced apoptosis by wild-type p53
which also induces p21, as well as the p53-independent induction
of p21 by AKBA, suggested a role for p21 as an effector of
AKBA-induced apoptosis. To clarify this issue, we compared the
isogenic wild-type human colorectal cancer cell line HCT116 with
sublines with heterozygous or homozygous p21 gene disruptions
for their sensitivity to AKBA (Figure 4B).
Interestingly, p21 disruption in these cells enhanced rather than
decreased sensitivity to apoptosis. Thus, although these cells did
not up-regulate p21 protein expression in response to AKBA and
may not reflect the biology of glial tumour cell lines, these obser-
vations imply a cytoprotective rather than apoptosis messenger
role for p21. Interestingly, p21 has been found to accumulate in
gliomas in vivo (Jung et al, 1995) and may mediate the cytoprotec-
tive effects of steroids in glioma cells (Naumann et al, 1998).
Further, p21 is now attributed a general role in inhibiting drug-
induced apoptosis in glial and non-glial tumour cells (Sheikh et al,
1997; Ruan et al, 1998).
CD95 is a novel target of immunotherapy for malignant glioma
(Weller et al, 1994; Weller et al, 1995a). Interestingly, the LOX
inhibitor, NDGA, inhibits CD95L-induced apoptosis of glioma
cells (Wagenknecht et al, 1997a). Yet, boswellic acids that are also
LOX inhibitors synergize with CD95L in inducing apoptosis
(Figure 6). Thus, NDGA may block apoptosis via mechanisms
unrelated to LOX inhibition or boswellic acids synergistically
enhance CD95L-induced apoptosis independent of LOX inhibi-
tion. Here, the concentrations required for boswellic acid-mediated
augmentation of CD95L-induced apoptosis probably exceed those
required for LOX inhibition (Sailer et al, 1996; Heldt et al, 1997),
but parallel those required for inhibition of RNA synthesis (Figure
6E), suggesting that an ActD-like effect (Weller et al, 1994) is
responsible for the synergy of AKBA and CD95L. Thus, AKBA is
a rather unique pro-apoptotic agent that inhibits RNA synthesis
(Figure 6E) but requires new protein synthesis, possibly from
mRNAs with a long half-life, to mediate toxicity (Figure 1E).
While preliminary data indicate that boswellic acids inhibit topo-
isomerase I and II activity (Heldt et al, 1997; Hoernlein et al,
1997), this effect of boswellic acids differs from those of classical
inhibitors, such as camptothecin or teniposide, which induce
cleavable DNA/topoisomerase I/II complex formation in the
glioma cells (Weller et al, 1997c) (Figure 6G). Incidently, we find
that potentiation of CD95L-induced apoptosis of human glioma
cells by camptothecin and topotecan, similar to that of boswellic
acids (Figure 6E), correlates with inhibition of RNA synthesis
(Winter and Weller, 1998). Boswellic acid-induced changes of
CD95 expression were excluded as a mechanism of synergy
(Figure 6 C,D). Note that the same concentrations of AKBA that
sensitize for acute CD95L-induced apoptosis kill glioma cells
upon longer exposure by an apoptotic pathway that requires new
protein synthesis (Figure 1E).
At present, defined drug formulations containing boswellic
acids are not available, and the preliminary putatively beneficial
effects of boswellic acids on the oedema of glioma patients (Böker
and Winking, 1997) were obtained with tablets that contain unde-
termined amounts of various boswellic acids. Thus, one may not
judge systemic toxicity and anti-oedema activity of pure boswellic
acids. Yet, the low systemic toxicity of the available drug formula-
tions (Gupta et al, 1997) is certainly promising. From a clinical
point of view, the lack of interference of boswellic acids with
chemotherapeutic drug-induced apoptosis of glioma cells (Figure
5) is highly relevant. We are currently performing a phase I/II clin-
ical trial to confirm the efficacy of boswellic acids for oedema
control in glioma patients with prominent cerebral oedema. Such
patients currently depend on steroid medications which have
significant side-effects and probably limit the efficacy of
chemotherapy (Weller et al, 1997a). The anti-oedema actions of
boswellic acids alone would make them a valuable addition to the
limited medical options in the treatment of malignant glioma,
specifically because these agents might allow for more effective
chemotherapy. Whether the pro-apoptotic effects of low micro-
molar AKBA concentrations characterized here (Figures 1–6)
have any clinical relevance, remains to be determined. The lack of
specificity for the neoplastic phenotype of glioma cells (Figures 1
and 9) suggests that boswellic acids acquire clinical significance in
neuro-oncology for their anti-oedema action, but not as tumour-
cytotoxic agents. Yet, cytotoxicity studies with neonatal astro-
cytes, which are proliferating cells, as performed here, do not
necessarily predict neurotoxicity in vivo, and preliminary studies
in laboratory animals suggest that boswellic acids may inhibit the
growth of glioma in the absence of intolerable side-effects
(Winking et al, 1998).
ACKNOWLEDGEMENTS
The authors thank Dr B Vogelstein (Baltimore, MD, USA) for
p21+/+, p21+/– and p21–/– human colon carcinoma cells, Dr A
Strasser (Victoria, Australia) for the CRM-A expression plasmid,
and Dr M Winking (Giessen, Germany) for valuable discussions.
This study was supported by the BMBF and the Deutsche
Forschungsgemeinschaft.
REFERENCES
Ammon HPT (1996) Salai Guggal-Boswellia serrata: From a herbal medicine to a
non redox inhibitor of leukotriene biosynthesis. Eur J Med Res 1: 369–370
Böker DK and Winking M (1997) Die Rolle von Boswellia-Säuren in der Therapie
maligner Gliome. Deutsches ￿rzteblatt 94: B958–B960
Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA and
Yung WKA (1997) Characterization of p53 and p21 functional interactions in
glioma cells en route to apoptosis. J Natl Cancer Inst 89: 1036–1044
Gupta I, Parihar A, Malhotra P, Singh GB, Lüdtke R, Safayhi H and Ammon HPT
(1997) Effects of boswellia serrata gum resin in patients with ulcerative colitis.
Eur J Med Res 2: 37–43
Heldt RM, Syrovets T, Winking M, Sailer ER, Safayhi H, Ammon HPT and Simmet
Th (1997) Boswellic acids exhibit cytotoxic effects on brain tumor cells
independent from 5-lipoxygenase inhibition. Naunyn-S-Arch Pharmacol 355:
30 (Abstract)
Hoernlein RF, Orlikowsky Th, Niethammer D, Sailer E-R, Dannecker GE and
Ammon HPT (1997) Acetyl-11-keto-b-boswellic acid (AKBA) induces
apoptosis in HL60 and CCRF-CEM cells and inhibits topoisomerase I. Soc
Cancer Res 1291 (Abstract)
Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA
and Zhang W (1995) Increased levels of p21WAF1/Cip1 in human brain tumors.
Oncogene 11: 2021–2028Boswellic acids for malignant glioma 765
British Journal of Cancer (1999) 80(5/6), 756–765 © Cancer Research Campaign 1999
Michalowitz D, Halevy O and Oren M (1990) Conditional inhibition of
transformation and of cell proliferation by a temperature-sensitive mutant of
p53. Cell 62: 674–680.
Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction
of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391–3395
Naumann U, Durka S and Weller M (1998) Dexamethasone-mediated protection
from drug toxicity linked to p21WAF/CIP1 protein accumulation. Oncogene 17:
1567–1575
Roth W, Fontana A, Trepel M, Dichgans J, Reed JC and Weller M (1997)
Immunochemotherapy of malignant glioma: synergistic activity of CD95
ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55–63
Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J
and Weller M (1998) Potentiation of treosulfan toxicity by the glutathione-
depleting agent, buthionine sulfoximine, in human malignant glioma cells: the
role of bcl-2. Biochem Pharmacol 55: 349–359
Rowe TC, Chen GL, Hsiang YH and Liu LF (1986) DNA damage by antitumor
acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46:
2021–2026
Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff, Levin V and Zhang W (1998)
Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to
chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
Cancer Res 58: 1538–1543
Safayhi H, Mack T, Sabieraj J and Ammon HPT (1992) Boswellic acids: novel,
specific non-redox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261:
1143–1146
Safayhi H, Sailer ER and Ammon HPT (1995) Mechanism of 5-lipoxygenase
inhibition by acetyl-11-keto-b-boswellic acids. Mol Pharmacol 47: 1212–1216
Safayhi H, Rall B, Sailer ER and Ammon HPT (1997) Inhibition by boswellic acids
of human leukocyte elastase. J Pharmocol Exp Ther 281: 460–463
Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HPT and Safayhi H
(1996) Acetyl-11-keto-b-boswellic acid (AKBA): structure requirements
for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 117:
615–618
Schulz JB, Weller M and Klockgether T (1996) A sequential requirement for new
mRNA and protein synthesis, ICE-like protease activity, and free radicals in
potassium deprivation-induced apoptosis of cerebellar granule cells. J Neurosci
16: 4696–4706
Sheikh M, Chen YQ, Smith ML and Fornace AJ (1997) Role of p21Waf1/Cip1/Sdi1 in cell
death and DNA repair as studied using a tetracycline-inducible system in p53-
deficient cells. Oncogene 14: 1875–1882
Strasser A, Harris AW, Huang DC, Krammer PH and Cory S (1995) Bcl-2 and
Fas/Apo-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14:
6136–6147
Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J and Weller M (1998)
Chemosensitivity of human malignant glioma: modulation by p53 gene
transfer. J Neuro-Oncol 39: 19–32
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS,
Friedmann T, De Tribolet N and Cavenee WK (1994) Analysis of the p53
gene and its expression in human glioblastoma cells. Cancer Res 54: 649–652
Wagenknecht B, Gulbins E, Lang F, Dichgans J and Weller M (1997a) Lipoxygenase
inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma
cells. FEBS Lett 409: 17–23
Wagenknecht B, Trepel M, von Deimling A, Grimmel C, Rollbrocker B, Hayashi Y,
Lang F, Dichgans J, Gulbins E and Weller M (1997b) p53 accumulation
promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein
in human malignant glioma cells. Cell Physiol Biochem 7: 304–311
Wagenknecht B, Schulz JB, Gulbins E and Weller M (1998) CD95L-induced
apoptosis of malignant glioma cells: inhibition of the cascade by crm-A, bcl-2,
and NDGA. Cell Death Differ 5: 894–900
Waldman T, Kinzler KW and Vogelstein B (1995) p21 is necessary for the p53-
mediated G1 arrest in human cancer cells. Cancer Res 55: 5187–5190
Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S
phase and mitosis induced by anticancer agents in cells lacking p21. Nature
381: 713–716
Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y and Fontana A (1994)
Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant
glioma cells. Induction and modulation of sensitivity by cytokines. J Clin
Invest 94: 954–964
Weller M, Malipiero UV, Aguzzi A, Reed JC and Fontana A (1995a) Protooncogene
bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of
human malignant glioma cells and confers resistance to chemotherapeutic
drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643
Weller M, Malipiero U, Rensing-Ehl A, Barr P and Fontana A (1995b) Fas/APO-1
gene transfer for human malignant glioma. Cancer Res 55: 2936–2944
Weller M, Schmidt C, Roth W and Dichgans J (1997a) Chemotherapy of human
malignant glioma: prevention of efficacy by dexamethasone? Neurology 48:
1704–1709
Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S and Reed JC
(1997b) Hypericin-induced apoptosis of human malignant glioma cells is light-
dependent, independent of bcl-2 expression, and does not require wild-type
p53. Neurol Res 19: 459–470
Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J and Groscurth P
(1997c) Topoisomerase I inhibitors for human malignant glioma. Differential
modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated
apoptosis by camptothecin and b-lapachone. Int J Cancer 73: 707–714
Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC,
von Deimling A and Dichgans J (1998) Predicting chemoresistence in human
malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79:
640–644
Winking M, Sarikya S, Jödicke A and Böker DK (1998) Boswellic acids inhibit
glioma growth. J Cancer Res Clin Oncol 124: R141 (Abstr.)
Winter S, Roth W, Dichgans J and Weller M (1998) Synergy of CD95 ligand and
teniposide: no role of cleavable complex formation and enhanced CD95
expression. Eur J Pharmacol 341: 323–328
Winter S and Weller M (1998) Potentiation of CD95L-induced apoptosis of human
malignant glioma cells by topotecan involves inhibition of RNA synthesis but
not changes in CD95 or CD95L expression. J Pharmacol Exp Ther 286:
1374–1382